Company news

Immatics N.V. news in 2026

Immatics N.V.'s news releases, calls and decks from 2026, newest first.

View company

Immatics Presents Clinical Activity of IMA402 PRAME Bispecific and IMA203CD8 PRAME Cell Therapy across Advanced Solid Tumors in Two Oral Presentations at 2026 ESMO Annual Meeting

October 24, 2026

Immatics Announces $150 Million Underwritten Offering

August 25, 2026

Immatics N Announces Second Quarter 2026 Financial Results and Business Update

August 18, 2026

Immunomic Therapeutics Announces First Patient Dosed in Phase 1 Trial of Cancer Vaccine Candidate ITI-5000

July 20, 2026

Immatics Announces Upcoming Presentations Across Its PRAME Franchise at ESMO Congress 2026

July 17, 2026

Immatics Presents Clinical Activity and Response Dynamics of Anzu-cel PRAME Cell Therapy at 2026 ASCO Annual Meeting

May 31, 2026

Immatics Presents Data on IMA401 MAGEA4/8 Bispecific at 2026 ASCO Annual Meeting with Simultaneous Publication in Nature Medicine Supporting Development of IMA401/IMA402 Combination in Lung Cancer

May 31, 2026

Immatics Presents Clinical Activity of IMA203CD8 PRAME Cell Therapy in Hard-to-Treat Gynecologic Cancers at 2026 ASCO Annual Meeting

May 29, 2026

Immatics Announces First Quarter 2026 Financial Results and Business Update

May 12, 2026

Immatics Announces Four Upcoming Oral Presentations Across Its Clinical Cell Therapy and Bispecific Portfolio at 2026 ASCO Annual Meeting

April 20, 2026

PRAME-directed Cell Therapy Using Immatics’ TCR Induces Deep and Durable Remission in Pediatric Patient with Advanced Metastatic Nephroblastoma

April 17, 2026

Immatics Announces Full Year 2025 Financial Results and Business Update

March 4, 2026

Decks in 2026